Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST2: Icatibant vs Tranexamic Acid in HAE
NCT00500656Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2005
- Primary completion
- Jul 2006
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of icatibant in hereditary angioedema (HAE) (4 arms), sponsored by Takeda. Primary endpoint: Time to Onset of Symptom Relief at 2 days. Started Mar 2005; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00500656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500656.